Web Analytics

3 Latest Announced Rounds

  • $23,000,000
    Unknown

    3 Investors

    Data Infrastructure and Analytics
    May 8th, 2025
  • $39,000,000
    Series B

    2 Investors

    Biotechnology Research
    May 8th, 2025
  • $50,000,000
    Series A
    Personal Care Product Manufacturing
    May 8th, 2025
$499.26M Raised in 43 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Glycomine Inc.

start up
United States - San Carlos, California
  • 17/04/2025
  • Series C
  • $115,000,000

Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.


Related People

Steven AxonFounder

Steven Axon United States - Cohasset, Massachusetts

Specialties: Biotech, Business Development,
Corporate Strategy, Corporate Finance, Alliance Management